SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
20 Noviembre 2023 - 6:30AM
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
is developing a fully-human anti-thymocyte immunoglobulin (hIgG)
for delaying the onset or progression of type 1 diabetes (T1D),
today announced that Katie Ellias has been appointed to the
Company’s Board of Directors.
With Ms. Ellias’ appointment, the SAB
Biotherapeutics Board is composed of ten directors, eight of whom
are independent. Ms. Ellias serves as a Managing Director at the
JDRF T1D Fund LLC, a venture philanthropy fund with approximately
$200 million in assets, including an investment in SAB. Ms. Ellias
joined the T1D Fund in 2018 where she has led a number of
investments in companies developing T1D-oriented therapies. She has
also served as a director on the board of several companies,
including, DiogenX, Veralox Therapeutics, i2O Therapeutics, and
Capillary Biomedical.
Ms. Ellias joined the T1D Fund from Endeavour
Vision, a Geneva-based growth stage venture fund. She was
previously Principal at Sofinnova Partners, Paris, a leading
early-stage life sciences fund. Ms. Ellias has also held roles in
business development with Medtronic and started her career at
McKinsey & Company. She holds an M.B.A. in Healthcare
Management from the Wharton School at the University of
Pennsylvania and a B.A. in International Relations and Political
Science from Yale University.
“Katie’s exceptional experience and deep
expertise in T1D are a natural fit for SAB’s Board of Directors,”
said Samuel J. Reich, Executive Chairman of SAB. “SAB is
well-positioned for growth; thus, we are grateful for the insight
and impact Katie will bring to our Board as we look to change the
T1D treatment paradigm.”
Ms. Ellias said, “SAB is well-positioned at a
critical inflection point in T1D. I’m inspired by what the company
is building and honored to join their Board of Directors.”
About SAB Biotherapeutics,
Inc.
SAB Biotherapeutics (SAB) is a clinical-stage
biopharmaceutical company focused on developing fully human, multi-
targeted, high-potency immunoglobulins (IgGs), without the need for
human donors or convalescent plasma, to treat and prevent immune
and autoimmune disorders. The company’s lead asset, SAB-142,
targets type 1 diabetes (T1D) with a disease-modifying therapeutic
approach that aims to change the treatment paradigm by delaying
onset and potentially preventing disease progression. Using
advanced genetic engineering and antibody science to develop
Transchromosomic (Tc) Bovine™, the only transgenic animal with a
human artificial chromosome, SAB’s DiversitAb™ drug development
production system is able to generate a diverse repertoire of
specifically targeted, high-potency, fully-human IgGs that can
address a wide range of serious unmet needs in human diseases
without the need for convalescent plasma or human donors. For more
information on SAB, visit: https://www.SAb.bio/.
Forward-Looking Statements
Certain statements made herein that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally are
accompanied by words such as “believe,” “may,” “will,” “to be,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”
“outlook,” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to,
statements regarding future events, including the development and
efficacy of our T1D program, and other discovery programs, the
closing of each tranche of the Company’s private placement
offering, the timely funding to the Company by each investor in the
private placement offering, financial projections and future
financial and operating results (including estimated cost savings
and cash runway), the outcome of and potential future government,
and other third-party collaborations or funded programs.
These statements are based on the current
expectations of SAB and are not predictions of actual performance,
and are not intended to serve as, and must not be relied on, by any
investor as a guarantee, prediction, definitive statement, or an
assurance, of fact or probability. These statements are only
current predictions or expectations, and are subject to known and
unknown risks, uncertainties and other factors which may be beyond
our control. Actual events and circumstances are difficult or
impossible to predict, and these risks and uncertainties may cause
our or our industry’s results, performance, or achievements to be
materially different from those anticipated by these
forward-looking statements. A further description of risks and
uncertainties can be found in the sections captioned “Risk Factors”
in our most recent annual report on Form 10-K, as amended,
subsequent quarterly reports on Form 10-Q, as may be amended or
supplemented from time to time, and other filings with or
submissions to, the U.S. Securities and Exchange Commission, which
are available at https://www.sec.gov/. Except as otherwise
required by law, SAB disclaims any intention or obligation to
update or revise any forward-looking statements, which speak only
as of the date they were made, whether as a result of new
information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:SAbPR@westwicke.com
Investor
Relations:matt@milestone-advisorsllc.com
SAB Biotherapeutics (NASDAQ:SABSW)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Gráfica de Acción Histórica
De May 2023 a May 2024